The unique nature of patient-reported outcome (PRO) measures presents unique challenges for translation. Regulators emphasise the importance of maintaining conceptual equivalence across all languages in multilingual
and multinational trials, while making necessary cultural adaptations. This article will provide an overview of the central issues affecting PRO measure translation, best practices for PRO measure translation, and ways
to improve the translatability of PRO measures at the development stage.